Terms: = Uterine cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Prognosis
86 results:
1. A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.
Liu YL; Weigelt B
Cancer; 2024 May; 130(10):1733-1746. PubMed ID: 38422006
[TBL] [Abstract] [Full Text] [Related]
2. Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Endometrial cancer: A Review on Immunohistochemistry Staining Patterns and Clinical Implications.
Addante F; d'Amati A; Santoro A; Angelico G; Inzani F; Arciuolo D; Travaglino A; Raffone A; D'Alessandris N; Scaglione G; Valente M; Tinnirello G; Sfregola S; Padial Urtueta B; Piermattei A; Cianfrini F; Mulè A; Bragantini E; Zannoni GF
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256131
[TBL] [Abstract] [Full Text] [Related]
3. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to mlh1 Promoter Hypermethylation.
Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
[TBL] [Abstract] [Full Text] [Related]
4. Cervical lymphoepithelioma-like carcinoma with deficient mismatch repair and loss of SMARCA4/BRG1: a case report and five related cases.
Miyama Y; Kato T; Sato M; Yabuno A; Hasegawa K; Yasuda M
Diagn Pathol; 2024 Jan; 19(1):6. PubMed ID: 38178127
[TBL] [Abstract] [Full Text] [Related]
5. Specific Pathology Features Enrich Selection of Endometrial Carcinomas for POLE Testing.
Keyhanian K; Han L; Howitt BE; Longacre T
Am J Surg Pathol; 2024 Mar; 48(3):292-301. PubMed ID: 38062789
[TBL] [Abstract] [Full Text] [Related]
6. Mismatch Repair Protein Deficiency Does Not Affect Disease Free Survival in Type I Endometrial Carcinoma.
Angelina YA; Tjokroprawiro BA; Sandhika W
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3229-3234. PubMed ID: 37774076
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Classification of Endometrial Endometrioid Carcinoma With Microcystic Elongated and Fragmented Pattern.
Ju B; Wu J; Sun L; Yang C; Yu H; Hao Q; Wang J; Zhang H
Int J Gynecol Pathol; 2024 May; 43(3):233-241. PubMed ID: 37733028
[TBL] [Abstract] [Full Text] [Related]
8. Analysis of patients with endometrial carcinoma using the ProMise classifier: a pilot study from India.
Dahiya A; Rajadurai A; Daniel S; Sebastian A; Thomas DS; Thomas V; George R; Ram TS; Sathyamurthy A; Rebekah G; Peedicayil A; Pai R; Thomas A
Arch Gynecol Obstet; 2024 Apr; 309(4):1499-1508. PubMed ID: 37707553
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer.
Kim MK; So KA; Chun YK; Kim YH; Lim KT; Lee KH; Kim TJ
Taiwan J Obstet Gynecol; 2023 Sep; 62(5):724-728. PubMed ID: 37679002
[TBL] [Abstract] [Full Text] [Related]
10. Concordance in detection of microsatellite instability by PCR and NGS in routinely processed tumor specimens of several cancer types.
Bartels S; Grote I; Wagner M; Boog J; Schipper E; Reineke-Plaass T; Kreipe H; Lehmann U
Cancer Med; 2023 Aug; 12(16):16707-16715. PubMed ID: 37376830
[TBL] [Abstract] [Full Text] [Related]
11. The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: Correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes.
Atılgan AO; Tepeoğlu M; Özen Ö; Reyhan ANH; Ayhan A
Ann Diagn Pathol; 2023 Aug; 65():152137. PubMed ID: 37060883
[TBL] [Abstract] [Full Text] [Related]
12. [Endometrioid adenocarcinoma with proliferated stromal cells, hyalinization and cord-like formations: A case report].
Ning BH; Zhang QX; Yang H; Dong Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):366-369. PubMed ID: 37042152
[TBL] [Abstract] [Full Text] [Related]
13. Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols.
Yang Z; Yang X; Liu X; Ma K; Meng YT; Yin HF; Wen J; Yang JH; Zhen Z; Feng ZH; Liao QP
BMC Cancer; 2023 Mar; 23(1):243. PubMed ID: 36918828
[TBL] [Abstract] [Full Text] [Related]
14. Application of molecular classification to guiding fertility-sparing therapy for patients with endometrial cancer or endometrial intraepithelial neoplasia.
Zhang X; Chen D; Zhao X; Wang C; He Y; Chen Y; Wang J; Shen D
Pathol Res Pract; 2023 Jan; 241():154278. PubMed ID: 36580798
[TBL] [Abstract] [Full Text] [Related]
15. Association of immunohistochemical profiles with histotypes in endometrial carcinomas.
Lin CM; Lin SF; Lee YC; Lai HC; Liew PL
Taiwan J Obstet Gynecol; 2022 Sep; 61(5):823-829. PubMed ID: 36088051
[TBL] [Abstract] [Full Text] [Related]
16. Isolated mlh1 Loss by Immunohistochemistry Because of Benign Germline
Bosch DE; Yeh MM; Salipante SJ; Jacobson A; Cohen SA; Konnick EQ; Paulson VA
JCO Precis Oncol; 2022 Aug; 6():e2200227. PubMed ID: 36044719
[TBL] [Abstract] [Full Text] [Related]
17. Clinicopathologic association and prognostic impact of microcystic, elongated and fragmented pattern invasion, combined with tumor budding in endometrioid endometrial cancer.
Qi X; Zhu L; Zhang B
J Obstet Gynaecol Res; 2022 Sep; 48(9):2431-2441. PubMed ID: 35769021
[TBL] [Abstract] [Full Text] [Related]
18. Analysis of the immune checkpoint lymphocyte activation gene-3 (LAG-3) in endometrial cancer: An emerging target for immunotherapy.
Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
Pathol Res Pract; 2022 Aug; 236():153990. PubMed ID: 35749914
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathologic significance of DNA mismatch repair protein status in endometrial cancer.
Kim JH; Kwon BS; Kim H; Suh DH; Kim K; Kim YB; No JH
Taiwan J Obstet Gynecol; 2022 May; 61(3):415-421. PubMed ID: 35595431
[TBL] [Abstract] [Full Text] [Related]
20. The clinical features and management of Lynch syndrome-associated ovarian cancer.
Ran X; Jing H; Li Z
J Obstet Gynaecol Res; 2022 Jul; 48(7):1538-1545. PubMed ID: 35478369
[TBL] [Abstract] [Full Text] [Related]
[Next]
